MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
23.13
+0.42
+1.85%
After Hours: 23.13 0 0.00% 16:01 02/23 EST
OPEN
22.67
PREV CLOSE
22.71
HIGH
23.51
LOW
22.67
VOLUME
870.54K
TURNOVER
0
52 WEEK HIGH
26.32
52 WEEK LOW
11.22
MARKET CAP
1.96B
P/E (TTM)
-8.9471
1D
5D
1M
3M
1Y
5Y
Barclays Releases a Buy Rating on Syndax Pharmaceuticals (SNDX)
TipRanks · 4d ago
Weekly Report: what happened at SNDX last week (0212-0216)?
Weekly Report · 6d ago
Weekly Report: what happened at SNDX last week (0205-0209)?
Weekly Report · 02/12 09:02
Syndax Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 02/09 22:30
Syndax Pharmaceuticals Inc: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/08 16:16
Weekly Report: what happened at SNDX last week (0129-0202)?
Weekly Report · 02/05 09:02
Investors growing more bullish on SMID cap biotech stocks
Investors growing more bullish on SMID cap biotech stocks. Merus and Fusion viewed as most likely to outperform the broader market this year. Investors are bullish on small caps and warming up to mid-caps, according to a TD Cowen investor sentiment survey. The IPO market is also expected to warm up.
Seeking Alpha · 02/04 22:16
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform, Lowers Price Target to $23
Benzinga · 01/31 14:58
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 (revumenib) and SNDX-6352 (axatilimab). It is focused on developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged (MLLr), acute leukemias including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and nucleophosmin 1 (NPM1) mutant AML. Its axatilimab, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis (IPF). Its products candidate also includes entinostat, an oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.